DBV Technologies (NASDAQ:DBVT) Receives “Market Outperform” Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock.

DBVT has been the subject of a number of other reports. StockNews.com began coverage on DBV Technologies in a report on Thursday. They set a “hold” rating for the company. HC Wainwright lifted their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Trading Up 29.8 %

DBVT stock opened at $4.97 on Friday. The stock has a 50-day moving average price of $3.32 and a two-hundred day moving average price of $3.83. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.49. The stock has a market cap of $102.23 million, a PE ratio of -1.10 and a beta of 0.64.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.